Search

Your search keyword '"Navone, Nora M"' showing total 444 results
Start Over Author "Navone, Nora M"
444 results on '"Navone, Nora M"'

1. Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations

Author

Habowski, Amber N, Budagavi, Deepthi P, Scherer, Sandra D, Aurora, Arin B, Caligiuri, Giuseppina, Flynn, William F, Langer, Ellen M, Brody, Jonathan R, Sears, Rosalie C, Foggetti, Giorgia, Estape, Anna Arnal, Nguyen, Don X, Politi, Katerina A, Shen, Xiling, Hsu, David S, Peehl, Donna M, Kurhanewicz, John, Sriram, Renuka, Suarez, Milagros, Xiao, Sophie, Du, Yuchen, Li, Xiao-Nan, Navone, Nora M, Labanca, Estefania, and Willey, Christopher D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Biotechnology, Cancer, Good Health and Well Being, patient derived models of cancer, organoids, mouse models, sequencing, tumor microenvironment, tumor cells, metastasis, Oncology and carcinogenesis
Abstract

For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to the forefront of preclinical cancer models and are even finding their way into clinical practice as part of functional precision medicine programs. The PDMC Consortium, supported by the Division of Cancer Biology in the National Cancer Institute of the National Institutes of Health, seeks to understand the biological principles that govern the various PDMC behaviors, particularly in response to perturbagens, such as cancer therapeutics. Based on collective experience from the consortium groups, we provide insight regarding PDMCs established both in vitro and in vivo, with a focus on practical matters related to developing and maintaining key cancer models through a series of vignettes. Although every model has the potential to offer valuable insights, the choice of the right model should be guided by the research question. However, recognizing the inherent constraints in each model is crucial. Our objective here is to delineate the strengths and limitations of each model as established by individual vignettes. Further advances in PDMCs and the development of novel model systems will enable us to better understand human biology and improve the study of human pathology in the lab.

Published
2024

2. Prostate lineage-specific metabolism governs luminal differentiation and response to antiandrogen treatment

Author

Giafaglione, Jenna M, Crowell, Preston D, Delcourt, Amelie ML, Hashimoto, Takao, Ha, Sung Min, Atmakuri, Aishwarya, Nunley, Nicholas M, Dang, Rachel MA, Tian, Mao, Diaz, Johnny A, Tika, Elisavet, Payne, Marie C, Burkhart, Deborah L, Li, Dapei, Navone, Nora M, Corey, Eva, Nelson, Peter S, Lin, Neil YC, Blanpain, Cedric, Ellis, Leigh, Boutros, Paul C, and Goldstein, Andrew S

Subjects
Biochemistry and Cell Biology, Biological Sciences, Urologic Diseases, Prostate Cancer, Aging, Cancer, Aetiology, 1.1 Normal biological development and functioning, 2.1 Biological and endogenous factors, Underpinning research, Male, Humans, Prostate, Monocarboxylic Acid Transporters, Cell Differentiation, Epithelial Cells, Androgen Antagonists, Lactates, Medical and Health Sciences, Developmental Biology, Biochemistry and cell biology
Abstract

Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes are well known to drive prostate lineage transitions, it remains unclear how upstream metabolic signalling contributes to the regulation of prostate epithelial identity. To fill this gap, we developed an approach to perform metabolomics on primary prostate epithelial cells. Using this approach, we discovered that the basal and luminal cells of the prostate exhibit distinct metabolomes and nutrient utilization patterns. Furthermore, basal-to-luminal differentiation is accompanied by increased pyruvate oxidation. We establish the mitochondrial pyruvate carrier and subsequent lactate accumulation as regulators of prostate luminal identity. Inhibition of the mitochondrial pyruvate carrier or supplementation with exogenous lactate results in large-scale chromatin remodelling, influencing both lineage-specific transcription factors and response to antiandrogen treatment. These results establish reciprocal regulation of metabolism and prostate epithelial lineage identity.

Published
2023

3. Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Author

Xiao, Lanbo, Parolia, Abhijit, Qiao, Yuanyuan, Bawa, Pushpinder, Eyunni, Sanjana, Mannan, Rahul, Carson, Sandra E., Chang, Yu, Wang, Xiaoju, Zhang, Yuping, Vo, Josh N., Kregel, Steven, Simko, Stephanie A., Delekta, Andrew D., Jaber, Mustapha, Zheng, Heng, Apel, Ingrid J., McMurry, Lisa, Su, Fengyun, Wang, Rui, Zelenka-Wang, Sylvia, Sasmal, Sanjita, Khare, Leena, Mukherjee, Subhendu, Abbineni, Chandrasekhar, Aithal, Kiran, Bhakta, Mital S., Ghurye, Jay, Cao, Xuhong, Navone, Nora M., Nesvizhskii, Alexey I., Mehra, Rohit, Vaishampayan, Ulka, Blanchette, Marco, Wang, Yuzhuo, Samajdar, Susanta, Ramachandra, Murali, and Chinnaiyan, Arul M.

Published
2024
Full Text
View/download PDF

4. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

Author

Crowell, Preston D., Giafaglione, Jenna M., Jones, Anthony E., Nunley, Nicholas M., Hashimoto, Takao, Delcourt, Amelie M.L., Petcherski, Anton, Agrawal, Raag, Bernard, Matthew J., Diaz, Johnny A., Heering, Kylie Y., Huang, Rong Rong, Low, Jin-Yih, Matulionis, Nedas, Navone, Nora M., Ye, Huihui, Zoubeidi, Amina, Christofk, Heather R., Rettig, Matthew B., Reiter, Robert E., Haffner, Michael C., Boutros, Paul C., Shirihai, Orian S., Divakaruni, Ajit S., and Goldstein, Andrew S.

Published
2023
Full Text
View/download PDF

6. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

Author

Xiao, Lanbo, Parolia, Abhijit, Qiao, Yuanyuan, Bawa, Pushpinder, Eyunni, Sanjana, Mannan, Rahul, Carson, Sandra E., Chang, Yu, Wang, Xiaoju, Zhang, Yuping, Vo, Josh N., Kregel, Steven, Simko, Stephanie A., Delekta, Andrew D., Jaber, Mustapha, Zheng, Heng, Apel, Ingrid J., McMurry, Lisa, Su, Fengyun, Wang, Rui, Zelenka-Wang, Sylvia, Sasmal, Sanjita, Khare, Leena, Mukherjee, Subhendu, Abbineni, Chandrasekhar, Aithal, Kiran, Bhakta, Mital S., Ghurye, Jay, Cao, Xuhong, Navone, Nora M., Nesvizhskii, Alexey I., Mehra, Rohit, Vaishampayan, Ulka, Blanchette, Marco, Wang, Yuzhuo, Samajdar, Susanta, Ramachandra, Murali, and Chinnaiyan, Arul M.

Published
2022
Full Text
View/download PDF

7. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

8. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

9. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, primary, Shepherd, Peter D.A., primary, Dong, Jiabin, primary, Yang, Jun, primary, Song, Xiaofei, primary, Nandakumar, Subhiksha, primary, Kundra, Ritika, primary, Lee, Cindy, primary, Schultz, Nikolaus, primary, Zhang, Jianhua, primary, Araujo, John C., primary, Aparicio, Ana M., primary, Subudhi, Sumit K., primary, Corn, Paul G., primary, Pisters, Louis L., primary, Ward, John F., primary, Davis, John W., primary, Vazquez, Elba S., primary, Gueron, Geraldine, primary, Logothetis, Christopher J., primary, Futreal, Andrew, primary, Troncoso, Patricia, primary, Chen, Yu, primary, and Navone, Nora M., primary

Published
2024
Full Text
View/download PDF

10. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

Author

Anselmino, Nicolas, primary, Labanca, Estefania, additional, Shepherd, Peter D.A., additional, Dong, Jiabin, additional, Yang, Jun, additional, Song, Xiaofei, additional, Nandakumar, Subhiksha, additional, Kundra, Ritika, additional, Lee, Cindy, additional, Schultz, Nikolaus, additional, Zhang, Jianhua, additional, Araujo, John C., additional, Aparicio, Ana M., additional, Subudhi, Sumit K., additional, Corn, Paul G., additional, Pisters, Louis L., additional, Ward, John F., additional, Davis, John W., additional, Vazquez, Elba S., additional, Gueron, Geraldine, additional, Logothetis, Christopher J., additional, Futreal, Andrew, additional, Troncoso, Patricia, additional, Chen, Yu, additional, and Navone, Nora M., additional

Published
2024
Full Text
View/download PDF

11. Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer

Author

Qiao, Yuanyuan, Choi, Jae Eun, Tien, Jean C., Simko, Stephanie A., Rajendiran, Thekkelnaycke, Vo, Josh N., Delekta, Andrew D., Wang, Lisha, Xiao, Lanbo, Hodge, Nathan B., Desai, Parth, Mendoza, Sergio, Juckette, Kristin, Xu, Alice, Soni, Tanu, Su, Fengyun, Wang, Rui, Cao, Xuhong, Yu, Jiali, Kryczek, Ilona, Wang, Xiao-Ming, Wang, Xiaoju, Siddiqui, Javed, Wang, Zhen, Bernard, Amélie, Fernandez-Salas, Ester, Navone, Nora M., Ellison, Stephanie J., Ding, Ke, Eskelinen, Eeva-Liisa, Heath, Elisabeth I., Klionsky, Daniel J., Zou, Weiping, and Chinnaiyan, Arul M.

Published
2021
Full Text
View/download PDF

12. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice.

Author

Lin, Song-Chang, Yu, Guoyu, Corn, Paul G., Damasco, Jossana, Lee, Yu-Chen, Song, Jian H., Navone, Nora M., Logothetis, Christopher J., Melancon, Marites P., Panaretakis, Theocharis, and Lin, Sue-Hwa

Subjects
OSTEOBLASTS, BONE density, RADIOTHERAPY, RESEARCH funding, T-test (Statistics), TRABECULECTOMY, COMPUTED tomography, PROSTATE tumors, DESCRIPTIVE statistics, MICE, ANIMAL experimentation, DATA analysis software
Abstract

Simple Summary: Radium 223 (Ra-223) is a radiopharmaceutical that targets tumor-induced osteoblasts (bone-forming cells). Ra-223 reduces bone pain and prolongs overall survival in men with bone-metastatic, castrate-resistant prostate cancer. However, increased fracture risk in skeletal sites with no bone metastasis has been observed in patients treated with Ra-223. The aim of this study was to examine the effects of Ra-223 on resident osteoblasts and normal bone structure in mouse models. Upon Ra-223 treatment, 70% of resident osteoblasts were reduced within 2 days, and the reduction lasted for at least 18 weeks. Ra-223 reduced the osteoblasts mainly localized in trabecular bone areas. Ra-223 also reduced bone mineral density and altered bone microstructure in the trabecular area of femurs. Furthermore, Ra-223 treatment also significantly reduced tumor-induced osteoblasts. These studies show that Ra-223 affects the structure of bones that are not involved in bone metastasis. Strategies that improve bone health may reduce fracture risk in patients receiving Ra-223. Radium 223 (Ra-223) is an α-emitting bone-homing radiopharmaceutical that targets tumor-induced osteoblasts and is used to reduce bone pain and prolong overall survival in men with bone-metastatic, castrate-resistant prostate cancer. However, increased fracture risk in skeletal sites with no bone metastasis has been observed in patients treated with Ra-223. Both luciferase- or green fluorescence protein (GFP)-labeled osteoblast reporter mice were used to monitor the effect of Ra-223 on resident osteoblasts and normal bone structure. Upon Ra-223 treatment, 70% of resident osteoblasts were reduced within 2 days, and the osteoblast reduction lasted for at least 18 weeks without detectable recovery, as measured by in vivo bioluminescent imaging. In GFP-labeled osteoblast reporter mice, Ra-223 mainly reduced osteoblasts localized in the trabecular bone areas; the osteoblasts in the growth plates were less affected. Micro-computed tomography analyses showed that Ra-223 significantly reduced bone mineral density and bone microstructure in the trabecular area of femurs but not in the cortical bone. Tumor-induced bone was generated by inoculating osteogenic TRAMP-BMP4 prostate cancer cells into the mouse femurs; Ra-223 treatment significantly reduced tumor-induced osteoblasts. Our study shows that Ra-223 affects bone structures that are not involved in bone metastasis. Strategies that improve bone health may reduce fracture risk in patients receiving Ra-223. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. The β-Secretase 1 Enzyme as a Novel Therapeutic Target for Prostate Cancer

Author

Rather, Hilal A., primary, Almousa, Sameh, additional, Kumar, Ashish, additional, Sharma, Mitu, additional, Pennington, Isabel, additional, Kim, Susy, additional, Su, Yixin, additional, He, Yangen, additional, Ghara, Abdollah R., additional, Sai, Kiran Kumar Solingapuram, additional, Navone, Nora M., additional, Vander Griend, Donald J., additional, and Deep, Gagan, additional

Published
2023
Full Text
View/download PDF

14. FIGURE 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

15. FIGURE 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

16. Data from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

17. FIGURE 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

18. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., additional, Song, Jian H., additional, Hoang, Anh, additional, Shepherd, Peter D. A., additional, Ramachandran, Sumankalai, additional, Navone, Nora M., additional, Efstathiou, Eleni, additional, Titus, Mark, additional, Corn, Paul G., additional, Lin, Sue-Hwa, additional, Logothetis, Christopher J., additional, and Panaretakis, Theocharis, additional

Published
2023
Full Text
View/download PDF

19. FIGURE 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

20. FIGURE 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

22. FIGURE 6 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

27. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3

Author

Salameh, Ahmad, Lee, Alessandro K, Cardó-Vila, Marina, Nunes, Diana N, Efstathiou, Eleni, Staquicini, Fernanda I, Dobroff, Andrey S, Marchiò, Serena, Navone, Nora M, Hosoya, Hitomi, Lauer, Richard C, Wen, Sijin, Salmeron, Carolina C, Hoang, Anh, Newsham, Irene, Lima, Leandro A, Carraro, Dirce M, Oliviero, Salvatore, Kolonin, Mikhail G, Sidman, Richard L, Do, Kim-Anh, Troncoso, Patricia, Logothetis, Christopher J, Brentani, Ricardo R, Calin, George A, Cavenee, Webster K, Dias-Neto, Emmanuel, Pasqualini, Renata, and Arap, Wadih

Subjects
Aging, Genetics, Prostate Cancer, Biotechnology, Cancer, Urologic Diseases, 2.1 Biological and endogenous factors, Aetiology, Adenosine Deaminase, Animals, Antigens, Neoplasm, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, HEK293 Cells, HeLa Cells, Humans, Immunoblotting, Introns, MCF-7 Cells, Male, Mice, SCID, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Protein Binding, RNA Interference, RNA Precursors, RNA, Long Noncoding, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Xenograft Model Antitumor Assays, PRUNE2, PCA3, long noncoding RNA, ADAR, prostate cancer, Hela Cells
Abstract

Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, which harbors the PCA3 locus, thereby classifying PCA3 as an antisense intronic long noncoding (lnc)RNA. We show that PCA3 controls PRUNE2 levels via a unique regulatory mechanism involving formation of a PRUNE2/PCA3 double-stranded RNA that undergoes adenosine deaminase acting on RNA (ADAR)-dependent adenosine-to-inosine RNA editing. PRUNE2 expression or silencing in prostate cancer cells decreased and increased cell proliferation, respectively. Moreover, PRUNE2 and PCA3 elicited opposite effects on tumor growth in immunodeficient tumor-bearing mice. Coregulation and RNA editing of PRUNE2 and PCA3 were confirmed in human prostate cancer specimens, supporting the medical relevance of our findings. These results establish PCA3 as a dominant-negative oncogene and PRUNE2 as an unrecognized tumor suppressor gene in human prostate cancer, and their regulatory axis represents a unique molecular target for diagnostic and therapeutic intervention.

Published
2015

28. Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer

Author

Chakravarthi, Balabhadrapatruni VSK, Dedigama-Arachchige, Pavithra, Carskadon, Shannon, Sundaram, Shanker Kalyana, Li, Jia, Wu, Kuan-Han Hank, Chandrashekar, Darshan Shimoga, Peabody, James O, Stricker, Hans, Hwang, Clara, Chitale, Dhananjay A, Williamson, Sean R, Gupta, Nilesh S, Navone, Nora M, Rogers, Craig, Menon, Mani, Varambally, Sooryanarayana, and Palanisamy, Nallasivam

Published
2019
Full Text
View/download PDF

29. Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Author

Brennen, W. Nathaniel, Le Magnen, Clémentine, Karkampouna, Sofia, Anselmino, Nicolas, Bock, Nathalie, Choo, Nicholas, Clark, Ashlee K., Coleman, Ilsa M., Dolgos, Robin, Ferguson, Alison M., Goode, David L., Krutihof-de Julio, Marianna, Navone, Nora M., Nelson, Peter S., O'Neill, Edward, Porter, Laura H., Ranasinghe, Weranja, Sunada, Takuro, Williams, Elizabeth D., and Butler, Lisa M.

Published
2024
Full Text
View/download PDF

30. Modeling Cancer Metastasis

Author

Navone, Nora M., Labanca, Estefania, Coleman, William B., Series editor, Tsongalis, Gregory J., Series editor, Wang, Yuzhuo, editor, Lin, Dong, editor, and Gout, Peter W., editor

Published
2017
Full Text
View/download PDF

32. The β-Secretase 1 Enzyme as a Novel Therapeutic Target for Prostate Cancer.

Author

Rather, Hilal A., Almousa, Sameh, Kumar, Ashish, Sharma, Mitu, Pennington, Isabel, Kim, Susy, Su, Yixin, He, Yangen, Ghara, Abdollah R., Sai, Kiran Kumar Solingapuram, Navone, Nora M., Vander Griend, Donald J., and Deep, Gagan

Subjects
ADENOCARCINOMA, DISEASE progression, XENOGRAFTS, HOMOGRAFTS, ANIMAL experimentation, IMMUNOHISTOCHEMISTRY, PROTEIN precursors, RATS, GENE expression, CELL cycle, ENZYMES, CELL proliferation, POSITRON emission tomography, DESCRIPTIVE statistics, RESEARCH funding, POLYMERASE chain reaction, CELL lines, PROSTATE tumors, MICE
Abstract

Simple Summary: Beta (β)-secretase 1, or β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), is an enzyme involved in processing the amyloid precursor protein (APP) leading to generation of the amyloid β (Aβ) peptide. The role of this pathway is well-established in various neurological disorders, and in the present study, we report the role of the BACE1 enzyme in prostate cancer (PCa) growth and progression. The expression of BACE1 and its downstream product, i.e., Aβ1-42 was observed in various PCa tissue samples and BACE1 activity was confirmed across various PCa cell lines. BACE1 inhibitor (MK-8931) treatment reduced the PCa cell proliferation and its in vivo administration inhibited TRAMP-C1 allograft growth in immuno-competent C57BL/6 mice. Overall, this study suggests BACE1 as a novel therapeutic target in PCa. Recent studies have demonstrated the association of APP and Aβ with cancer, suggesting that BACE1 may play an important role in carcinogenesis. In the present study, we assessed BACE1's usefulness as a therapeutic target in prostate cancer (PCa). BACE1 expression was observed in human PCa tissue samples, patient-derived xenografts (PDX), human PCa xenograft tissue in nude mice, and transgenic adenocarcinoma of the mouse prostate (TRAMP) tissues by immunohistochemistry (IHC) analysis. Additionally, the downstream product of BACE1 activity, i.e., Aβ1-42 expression, was also observed in these PCa tissues by IHC as well as by PET imaging in TRAMP mice. Furthermore, BACE1 gene expression and activity was confirmed in several established PCa cell lines (LNCaP, C4-2B-enzalutamide sensitive [S], C4-2B-enzalutamide resistant [R], 22Rv1-S, 22Rv1-R, PC3, DU145, and TRAMP-C1) by real-time PCR and fluorometric assay, respectively. Treatment with a pharmacological inhibitor of BACE1 (MK-8931) strongly reduced the proliferation of PCa cells in in vitro and in vivo models, analyzed by multiple assays (MTT, clonogenic, and trypan blue exclusion assays and IHC). Cell cycle analyses revealed an increase in the sub-G1 population and a significant modulation in other cell cycle stages (G1/S/G2/M) following MK-8931 treatment. Most importantly, in vivo administration of MK-8931 intraperitoneal (30 mg/kg) strongly inhibited TRAMP-C1 allograft growth in immunocompetent C57BL/6 mice (approximately 81% decrease, p = 0.019). Furthermore, analysis of tumor tissue using the prostate cancer-specific pathway array revealed the alteration of several genes involved in PCa growth and progression including Forkhead O1 (FOXO1). All together, these findings suggest BACE1 as a novel therapeutic target in advanced PCa. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer

Author

Li, Dan, primary, Zhan, Yu, additional, Wang, Naitao, additional, Tang, Fanying, additional, Lee, Cindy J., additional, Bayshtok, Gabriella, additional, Moore, Amanda R., additional, Wong, Elissa W. P., additional, Pachai, Mohini R., additional, Xie, Yuanyuan, additional, Sher, Jessica, additional, Zhao, Jimmy L., additional, Khudoynazarova, Makhzuna, additional, Gopalan, Anuradha, additional, Chan, Joseph, additional, Khurana, Ekta, additional, Shepherd, Peter, additional, Navone, Nora M., additional, Chi, Ping, additional, and Chen, Yu, additional

Published
2023
Full Text
View/download PDF

34. Supplemental Tables 1 and 2 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figure 3 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

36. Data from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

37. Supplemental Figure 1 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

38. Supplemental Information from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

39. Supplemental Figure Legends from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figure 2 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

41. Supplemental Figure 4 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

42. Table S2 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

Author

Tzelepi, Vassiliki, primary, Zhang, Jiexin, primary, Lu, Jing-Fang, primary, Kleb, Brittany, primary, Wu, Guanglin, primary, Wan, Xinhai, primary, Hoang, Anh, primary, Efstathiou, Eleni, primary, Sircar, Kanishka, primary, Navone, Nora M., primary, Troncoso, Patricia, primary, Liang, Shoudan, primary, Logothetis, Christopher J., primary, Maity, Sankar N., primary, and Aparicio, Ana M., primary

Published
2023
Full Text
View/download PDF

44. Legend of Supplementary Figures from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

Author

Corn, Paul G., primary, Zhang, Miao, primary, Nogueras-Gonzalez, Graciela M., primary, Xiao, Lianchun, primary, Zurita, Amado J., primary, Subudhi, Sumit K., primary, Tu, Shi-Ming, primary, Aparicio, Ana M., primary, Coarfa, Cristian, primary, Rajapakshe, Kimal, primary, Huang, Shixia, primary, Navone, Nora M., primary, Lin, Sue-Hwa, primary, Wang, Guocan, primary, Ramachandran, Sumankalai, primary, Titus, Mark A., primary, Panaretakis, Theocharis, primary, Gallick, Gary E., primary, Efstathiou, Eleni, primary, Troncoso, Patricia, primary, and Logothetis, Christopher, primary

Published
2023
Full Text
View/download PDF

47. Figure S7 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Methods from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features

Author

Tzelepi, Vassiliki, primary, Zhang, Jiexin, primary, Lu, Jing-Fang, primary, Kleb, Brittany, primary, Wu, Guanglin, primary, Wan, Xinhai, primary, Hoang, Anh, primary, Efstathiou, Eleni, primary, Sircar, Kanishka, primary, Navone, Nora M., primary, Troncoso, Patricia, primary, Liang, Shoudan, primary, Logothetis, Christopher J., primary, Maity, Sankar N., primary, and Aparicio, Ana M., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Results from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results